{"slideshow_credits": null, "snippet": "An independent monitor told the company it could proceed with a large clinical trial of Vytorin, Merck said.", "abstract": null, "section_name": "Business Day", "print_page": "", "document_type": "article", "byline": {"person": [], "organization": "REUTERS", "original": "By REUTERS", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/03/13/business/merck-cholesterol-trial-can-continue.html", "lead_paragraph": "An independent monitor told the company it could proceed with a large clinical trial of Vytorin, Merck said.", "headline": {"main": "Merck Cholesterol Trial Can Continue"}, "_id": "513f3067cf28d04ae00025d9", "word_count": "281", "multimedia": [], "pub_date": "2013-03-13T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Vytorin (Drug)", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Merck & Company Inc", "name": "organizations", "is_major": "N", "rank": "2"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "3"}], "blog": [], "subsection_name": null, "type_of_material": "News"}